OBESEMA 1.7 mg Multi-dose Disposable Pen Solution for Injection 3 ml

Product Introduction of Obesema (Semaglutide) 1.7mg Injection

Obesema 1.7mg Semaglutide Injection is an advanced dose designed for patients who have completed lower doses and need stronger appetite control and weight loss results.

Obesema (Semaglutide) 1.7mg Injection is a high-dose GLP-1 therapy specifically engineered for patients who have successfully navigated the initial titration phases. Manufactured by Alkem Laboratories Ltd, this advanced strength serves as the penultimate step toward the maximum maintenance dose. Specifically, it provides the intensified appetite suppression and metabolic support required to overcome weight-loss plateaus.

As a bioequivalent generic alternative to Wegovy 1.7mg, Obesema offers the same active ingredient and clinical efficacy at a significantly more accessible price point. Furthermore, this dose is critical for establishing the final biological foundation before moving to the 2.4mg maintenance level. By utilizing the 1.7mg pen, patients can ensure a smoother transition while maximizing fat loss and glycemic stability.

The Role of the 1.7mg Dose

According to FDA-approved dosing schedules, the 1.7mg strength is not a starting point. Instead, it is used to:

Deepen Satiety Signals: It targets the brain’s hunger centers more aggressively than the 1mg dose.

Optimize Fat Metabolism: Consequently, it helps patients achieve a higher percentage of total body weight loss.

Prepare for Maintenance: It acts as the final gateway to long-term chronic weight management.

1.7 mg semaglutide dose

Weekly injection

Step before 2.4mg maintenance dose

Supports significant fat loss

What is Obesema (Semaglutide) 1.7mg Injection??

Obesema (Semaglutide) 1.7mg Injection represents the penultimate dose in the semaglutide weight-loss escalation pathway delivering near-maximum GLP-1 receptor activation for significant and sustained body weight reduction. Manufactured by Alkem Laboratories Ltd, it is the affordable Indian generic equivalent of Wegovy 1.7mg by Novo Nordisk. Each pen kit includes 4 × 1.7mg weekly doses, 4 needles, and 4 alcohol swabs.

Obesema (Semaglutide) 1.7mg Injection represents the penultimate dose in the semaglutide weight-loss escalation pathway. Manufactured by Alkem Laboratories Ltd, it is the high-potency, affordable generic equivalent of Wegovy 1.7mg. This specific strength is designed for patients who have moved beyond the introductory levels and require near-maximum GLP-1 receptor activation for significant and sustained body weight reduction.

Advanced Therapeutic Support

Unlike the starter doses (0.25mg and 0.5mg) which focus on acclimation, the 1.7mg pen is a therapeutic powerhouse. Specifically, it contains a higher concentration of the active ingredient, Semaglutide, to target deep-seated metabolic receptors. As a result, patients typically experience a more profound suppression of appetite and a more consistent metabolic rate, helping to break through frustrating weight-loss plateaus.

Comprehensive Pen System

The Obesema 1.7mg system is provided as a complete 4-week treatment kit. Each package includes:

One Multi-dose Disposable Pen: Pre-filled with a total of 6.8mg of Semaglutide (delivering four 1.7mg doses).

Four Sterile Needles: For fresh, weekly subcutaneous administration.

Four Alcohol Swabs: To maintain injection site hygiene.

Furthermore, this multi-dose design ensures that patients in the USA, UK, and Australia can maintain their high-dose treatment schedule with extreme precision. Consequently, Obesema 1.7mg provides a reliable bridge between the mid-tier doses and the final 2.4mg maintenance phase.

Uses of Obesema (Semaglutide) 1.7mg Injection

The 1.7mg dose of Obesema is a high-potency treatment intended for advanced metabolic management. Specifically, this strength is utilized by patients who have successfully adjusted to lower doses but require a stronger biological signal to achieve their long-term health goals.

1. Advanced Chronic Weight Management

In the journey toward significant body weight reduction, the 1.7mg dose is used to:

Overcome Weight-Loss Plateaus: It provides the necessary GLP-1 receptor saturation to restart weight loss when progress stalls at lower strengths.

Deepen Appetite Suppression: Consequently, users experience a dramatic reduction in food noise and cravings for high-calorie, processed foods.

2. Metabolic and Glycemic Optimization

For adults managing weight-related comorbidities, Obesema 1.7mg is prescribed to:

Enhance Insulin Efficiency: It continues the process of improving how the body responds to glucose, ensuring stable energy levels throughout the day.

Maintain Hormonal Balance: Furthermore, it helps regulate the hormones responsible for satiety, making it easier to adhere to a calorie-restricted diet over several months.

3. Gateway to Maximum Maintenance

Because the 1.7mg strength is the penultimate dose, its primary use is to:

Assess High-Dose Tolerability

Bridge to 2.4mg

Chronic weight management in adults with obesity (BMI =30)

Weight loss in overweight adults (BMI =27) with weight-related comorbidities

Advanced dose in the semaglutide titration pathway preceding 2.4mg

Adjunct therapy in type 2 diabetes with obesity

How Obesema (Semaglutide) 1.7mg Injection Works

Semaglutide mimics the GLP-1 hormone:

Slows digestion

Reduces hunger

Improves insulin response

Controls blood sugar levels

Benefits of Obesema (Semaglutide) 1.7mg Injection

At 1.7mg, semaglutide provides near-maximal appetite suppression reducing hunger hormones, slowing gastric emptying, and enhancing satiety signals via hypothalamic GLP-1 receptors. Clinical trials show average weight loss of 12–15% of body weight at this dose over 68 weeks when combined with lifestyle intervention.

The 1.7mg dose is often referred to as the therapeutic acceleration phase.

Powerful Plateau Breaking

Intensified Appetite Suppression

Generic Cost Efficiency

Precision Multi-Dose Delivery

Enhanced Metabolic Health

Dosage of Obesema (Semaglutide) 1.7mg Injection

Administer once weekly on same day.

Remain on dose for 4 to 8 weeks.

Flexible timing allowed.

How to Use the 1.7mg Multi-dose Pen

Preparation: Clean injection site

Attach Needle

Dial Dose

Inject and hold for 6 seconds

Store properly

Missed Dose Protocol

Take within 5 days

Skip if beyond 5 days

Side Effects of Obesema (Semaglutide) 1.7mg Injection

Nausea

Vomiting

Diarrhea

Constipation

Fatigue

Safety Advice of Obesema (Semaglutide) 1.7mg Injection

All Substitutes

Ozempic Injection

Wegovy Injection

Obesema(Semaglutide) Injection

Sematrinity(Semaglutide) Injection

Noveltreat(Semaglutide) Injection

Semaglyn(Semaglutide) Injection

Noveltreat(Semaglutide) Injection

Glipiq(Semaglutide) Injection

Semanext(Semaglutide) Injection

Hepaglide(Semaglutide) Injection

Global Savings: Wegovy vs Obesema 1.7mg

FAQs about Obesema (Semaglutide) 1.7mg Injection

1. What is Obesema (Semaglutide) 1.7mg Injection used for?

Obesema (Semaglutide) 1.7mg Injection is used for advanced weight loss and chronic weight management. It is typically prescribed after lower doses as part of a structured semaglutide treatment plan.

This dose provides stronger appetite suppression and supports significant fat loss.

2. How does Obesema 1.7mg semaglutide work in the body?

Obesema works by mimicking the GLP-1 (glucagon-like peptide-1) hormone.

Slows gastric emptying to increase fullness

Reduces hunger signals

Enhances insulin secretion

Reduces glucose production

3. Is Obesema 1.7mg effective for weight loss?

Yes, Obesema 1.7mg is highly effective for weight loss and provides stronger results compared to lower doses.

It helps reduce appetite, cravings, and supports long-term fat loss.

4. Who should use Obesema 1.7mg Injection?

This dose is recommended for:

Patients progressing from lower doses

Individuals needing stronger weight loss support

People with obesity or overweight conditions

Use under medical supervision.

5. How should I take Obesema 1.7mg Injection?

Obesema 1.7mg is administered as a once-weekly subcutaneous injection.

Inject on the same day each week

Use abdomen, thigh, or upper arm

Rotate injection sites

Follow doctor instructions

6. How long does Obesema 1.7mg take to show results?

Typical results timeline:

Appetite reduction: 1–2 weeks

Weight loss begins: 3–5 weeks

Significant results: 8–12 weeks

7. What are the side effects of Obesema 1.7mg?

Common side effects include:

Nausea

Vomiting

Diarrhea

Constipation

Loss of appetite

These are usually temporary.

8. Is Obesema 1.7mg safe for long-term use?

Yes, Obesema 1.7mg is safe when used under medical supervision.

It supports long-term weight management and metabolic health.

9. Who should avoid using Obesema 1.7mg?

This medication may not be suitable for:

Pregnant or breastfeeding women

Patients with thyroid cancer history

Individuals with severe gastrointestinal disorders

People allergic to semaglutide

10. Where can I buy Obesema (Semaglutide) 1.7mg Injection online safely?

You can buy Obesema 1.7mg Injection from trusted online pharmacies.

Verify website authenticity

Ensure secure payment options

Check product reviews

Avoid unusually low prices

Consult a healthcare professional before use.

11. How does 1.7mg differ from 0.5mg or 1mg semaglutide?

Higher doses produce greater GLP-1 receptor activation, leading to more pronounced appetite suppression, greater average weight loss, and stronger HbA1c reductions. The 1.7mg dose is specifically part of the Wegovy dosing pathway designed for chronic weight management rather than diabetes alone.

12. How long should I stay on 1.7mg before going to 2.4mg?

Standard protocol recommends maintaining each dose for at least 4 weeks before escalating. Many patients achieve their weight-loss goals at 1.7mg and remain at this dose long-term rather than advancing to 2.4mg.

13. Is this safe without a diabetes diagnosis?

Yes. Semaglutide at 1.7mg is approved for chronic weight management regardless of diabetes status in many countries. It is prescribed for obesity (BMI =30) or overweight with comorbidities (BMI =27).

14. What dietary changes should accompany this treatment?

A moderate caloric deficit (500–750 kcal/day below maintenance), high-protein diet, and reduced processed food intake maximize weight-loss outcomes. This medication works synergistically with lifestyle modification, not as a replacement for it.

15. Can I travel internationally with semaglutide pens?

Yes, with proper documentation. Keep the pen refrigerated during travel (use an insulin travel case with ice packs). Carry a prescription or physician’s letter in English. Declare the medication at customs as required.

Medically Reviewed: Content is educational only. Consult a qualified healthcare provider before initiating semaglutide therapy.